Advanced search
1 file | 1.00 MB

Potential targets' analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine Leiomyosarcomas : an ENITEC Group Initiative

(2017) CLINICAL CANCER RESEARCH. 23(5). p.1274-1285
Author
Organization
Keywords
ENDOMETRIAL STROMAL SARCOMA, SOFT-TISSUE SARCOMA, GROWTH-FACTOR RECEPTOR, AKT-MTOR PATHWAY, MAMMALIAN TARGET, BREAST-CANCER, CYCLIN D1, EXPRESSION, TUMORS, TRIAL

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.00 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Cuppens, Tine, Daniela Annibali, An Coosemans, Jone Trovik, Natalja ter Haar, Eva Colas, Angel Garcia-Jimenez, et al. 2017. “Potential Targets’ Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas : an ENITEC Group Initiative.” Clinical Cancer Research 23 (5): 1274–1285.
APA
Cuppens, T., Annibali, D., Coosemans, A., Trovik, J., ter Haar, N., Colas, E., Garcia-Jimenez, A., et al. (2017). Potential targets’ analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine Leiomyosarcomas : an ENITEC Group Initiative. CLINICAL CANCER RESEARCH, 23(5), 1274–1285.
Vancouver
1.
Cuppens T, Annibali D, Coosemans A, Trovik J, ter Haar N, Colas E, et al. Potential targets’ analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine Leiomyosarcomas : an ENITEC Group Initiative. CLINICAL CANCER RESEARCH. 2017;23(5):1274–85.
MLA
Cuppens, Tine, Daniela Annibali, An Coosemans, et al. “Potential Targets’ Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas : an ENITEC Group Initiative.” CLINICAL CANCER RESEARCH 23.5 (2017): 1274–1285. Print.
@article{8578031,
  author       = {Cuppens, Tine and Annibali, Daniela and Coosemans, An and Trovik, Jone and ter Haar, Natalja and Colas, Eva and Garcia-Jimenez, Angel and Van de Vijver, Koen and Kruitwagen, Roy PM and Brinkhuis, Mariel and Zikan, Michal and Dundr, Pavel and Huvila, Jutta and Carpen, Olli and Haybaeck, Johannes and Moinfar, Farid and Salvesen, Helga B and Stukan, Maciej and Mestdagh, Carole and Zweemer, Ronald P and Massuger, Leonardus F and Mallmann, Michael R and Wardelmann, Eva and Mints, Miriam and Verbist, Godelieve and Thomas, Debby and Gomme, Ellen and Hermans, Els and Moerman, Philippe and Bosse, Tjalling and Amant, Frederic},
  issn         = {1078-0432},
  journal      = {CLINICAL CANCER RESEARCH},
  keywords     = {ENDOMETRIAL STROMAL SARCOMA,SOFT-TISSUE SARCOMA,GROWTH-FACTOR RECEPTOR,AKT-MTOR PATHWAY,MAMMALIAN TARGET,BREAST-CANCER,CYCLIN D1,EXPRESSION,TUMORS,TRIAL},
  language     = {eng},
  number       = {5},
  pages        = {1274--1285},
  title        = {Potential targets' analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine Leiomyosarcomas : an ENITEC Group Initiative},
  url          = {http://dx.doi.org/10.1158/1078-0432.CCR-16-2149},
  volume       = {23},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: